Reference
- Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Naturv 411, 355–365 (2001).
- Pawson T, Nash P Protein—protein interactions define specificity in signal transduction. Genes Dev. 14, 1027–1047 (2000).
- Reed JC. Dysregulation of apoptosis in cancer. j Clin. Oncol 17, 2941–2953 (1999).
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100, 57–70 (2000).
- Petricoin EF, Liotta LA. Proteomic analysis at the bedside: early detection of cancer. Trends Biotechnol 20, S30—S34 (2002).
- Liana L, Petricoin E. Molecular profiling of human cancer. Nature Rev Genet. 1, 48–56 (2000).
- Ideker T, Thorsson V, Ranish JA et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292, 929–934 (2001).
- Schwikowski B, Uetz P, Fields S. A network of protein—protein interactions in yeast. Nature Biotechnol 18, 1257–1261 (2000).
- Legrain P, Jestin JL, Schachter V. From the analysis of protein complexes to proteome-wide linkage maps. CUIT: Opin. Biotechnol. 11, 402–407 (2000).
- Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature 411,375–379 (2001).
- Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam, S. The protein kinase complement of the human genome. Science 298,1912–1934 (2002).
- Daucey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nature Rev Drug Discov. 2, 296–313 (2003).
- Futreal PA, Kasprzyk A, Birney E et aL Cancer and genomics. Nature 409, 850–852 (2001).
- Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 21,8541–8546 (2002).
- Joensuu H, Fletcher C, Dimitrijevic S et aL Management of malignant gastrointestinal stromal tumors. Lancet OncoL 3,655–664 (2002).
- Rubin BP, Schuetze SM, Eary JF etal. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. Clin. OncoL 20,3586–3591 (2002).
- Bogdanovic S, Langlands B. Protein kinases: technologies and opportunities for drug discovery. D & MD Reports (2003).
- Gallardo G, Tabraue C, Quintana J et al. Regulation by ceramide of epidermal growth factor signal transduction and mitogenesis in cell lines overexpressing the growth factor receptor. Cell. MoL Biol. 46, 1305–1312 (2000).
- Eccles SA. Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signaling. Rec. Res. Cancer Res. 157,41–54 (2000).
- Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7,2958–2970 (2001).
- Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drug activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053–2063 (2000).
- Milas L, Mason K, Hunter N etal, hi vivo enhancement of tumor radioresponse by C225 anti-epidermal growth factor antibody. Clin. Cancer Res. 6,701–708 (2000).
- Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6,2166–2174 (2000).
- Pruitt K, Der CJ. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171,1–10 (2001).
- Pollack PM, Meltzer PS. Lucky draw in the gene raffle. Nature 417,906–907 (2002).
- Grunicke HH, Maly K. Role of GTPases and GTPase regulatory proteins in oncogenesis. Crit. Rev OncoL 4,389–402 (1993).
- Davies H, Bignell GR, Cox C et aL Mutations of the BRAFgene in human cancer. Nature 417,949–954 (2002).
- Kerkoff E, Rappo UR. Cell cycle targets of Ras/Raf signaling. Oncogene 17, 1459–1462 (1998).
- Stanton VP, Cooper GM. Activation of human Raf transforming genes by deletion of normal amino-terminal coding sequences. MoL Cell. Biol. 7,1171–1179 (1987).
- Kolch W, Heidecker G, Kochs G et al. Protein kinase C-a activates Raf-1 by direct phosphorylation. Nature 364,249–252 (1993).
- Cornwell MM, Smith DE. A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. I Biol. Chem. 268, 15347–15350 (1993).
- Catling AD, Schaeffer HJ, Reuter CW, Reddy GR, Weber MJ. A praline rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. MoL Cell. Biol. 15,5214–5225 (1995).
- Vivanco I, Sawyers CL. The phosphoinositol 3-kinase Akt pathway in human cancer. Nature Rev Cancer 2, 489–501 (2002).
- Cantley LC. The phosphoinositide 3-kinase pathway. Science 296,1655–1657 (2002).
- Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollack M. Insulin-like growth factor-I signaling and resistance to trastuzamab (Herceptin). I Natl Cancer Inst. 93, 1852–1857 (2001).
- Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor I mediates resistance to anti-epidermal growth factor therapy in primary human gliablastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62,200–207 (2002).
- Angeles TS, Lippy JS, Yang SX. Quantitative, high-throughput cell based assays for inhibitors of trkA receptor. AnaL Biochem. 278,93–98 (2000).
- Waddleton D, Ramachandran C, Wang Q. Development of a time-resolved fluorescent assay for measuring tyrosine- phosphorylated proteins in cells. Anal. Biochem. 309,150–157 (2002).
- Kolb AJ, Burke, JW, Mathis G. Homogenous time resolved fluorescent method for drug discovery. In: High Throughput Screening. Devlin JP (Ed.), Marcel Dekker, NY, USA, 345–359 (1997).
- Glickman JF, Wu X, Mercuri R et al Comparison of AlphaScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors. J BiomoL Screen. 7,3–10 (2002).
- Zhang JH, Ching TDY, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J. BiomoL Screen. 4,67–73 (1999).
- Burke TJ, Loniello KR, Beebe JA et al Development and application of fluorescence polarization assays in drug discovery. Comb. Chem. High Throughput Screen. 6,183–194 (2003).
- Turek TC, Small EC, Bryant RW etal. Development and validation of a competitive AKT serine/threonine kinase fluorescence polarization assay using product-specific antiphospho-serine antibody. AnaL Biochem. 299,45–53 (2001).
- Banks P, Gosselin M, Prystay L. Impact of red-shifted dye label for high throughput fluorescence polarization assays of G-protein coupled receptors. J. BiomoL Screen. 5,329–334 (2000).
- Banks P, Gosselin M, Prystay L. Fluorescence polarization assays for high throughput screening of G-protein coupled receptors. J BiomoL Screen. 5,159–167 (2000).
- Fowler A, Swift D, Longman E et aL An evaluation of fluorescence polarization and lifetime discriminated polarization for high-throughput screening of serine/threonine kinases. Anal. Biochem. 308,223–231 (2002).
- Vedvik KL, Eliason HC, Hoffman RL et al. Overcoming compound interference in fluorescent polarization-based kinase assays using far-red tracers. Away Drug DeveL 2, 193–203 (2004).
- Beasley JR, Dunn DA, Walker TL et al. Evaluation of compound interference in immobilized metal ion affinity-based fluorescence polarization detection with a four million member compound collection. Assay Drug DeveL 1,455–459 (2003).
- Turek-Etienne TC, Kober TP, Stafford JM et al. Development of a fluorescence polarization AKT serine/threonine kinase assay using an immobilized metal ion affinity-based technology. Assay Drug DeveL 1,545–553 (2003).
- Gaudet EA, Huang KS, Zhang Y et al. A homogenous fluorescence polarization assay adaptable for a range of protein serine/threonine and tyrosine kinases. BiomoL Screen. 8,164–175 (2003).
- Lu Z, Yin Z, James L et aL Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase.j BiomoL Screen. 9,309–321 (2004).
- Loomans EEMG, van Doornmalen AM, Wat JWY et al. High throughput screening with immobilized metal ion affinity-based fluorescence polarization detection, a homogenous assay for protein kinases. Assay Drug DeveL 1,445–453 (2003).
- Anderson L, Porath J. Isolation of phosphoproteins by immobilized metal Fe3+ affinity chromatography. Anal. Biochem. 154,250–254 (1986).
- McCauley TJ, Stanaitis ML, Savage MD, Onken J, Millis SZ. IQ technology: development of a universal homogenous method for high-throughput screening of kinase and phosphatase activity. JAMA 8, 36–40 (2003).
- Morgan AG, McCauley TJ, Stanaitis ML, Mathrubutham M, Millis SZ. Development and validation of a fluorescence technology for both primary and secondary screening of kinases that facilitates compound selectivity and site-specific inhibitor determination. Assay Drug DeveL 2,171–181 (2004).
- Xia W, Rininsland F, Wittenburg SK et al. Applications of fluorescent polymer superquenching to high-throughput screening assays for protein kinases. Assay Drug DeveL 2,183–192 (2004).
- Cohen CB, Chin-Dixon E, Jeong S et al. A microchip-based enzyme assay for protein kinase A. Anal. Biochem. 273, 89–97 (1999).
- Dunne J, Reardon H, Trinh V et al. Comparison of on-chip and off-chip microfluidics kinase assay formats. Assay Drug DeveL 2,121–129 (2004).
- Chen H, Olive DM. Quantitative measurement of the activation of signaling pathways using two-color infrared fluorescent western blotting and cell-based assays. Proc. IBC Protein Kinases Meet. 7(March), (2002).
- Russello S. Assessing cellular protein phosphorylation: high-throughput drug development technologies. Assay Drug DeveL 2,225–235 (2004).
- Wong SK. A 384-well cell-based phospho-ERK assay for dopamine D2 and D3 receptors. Anal. Biochem. (In Press).
- Luttrell LM. Activation and targeting of mitogen-activated protein kinases by G-protein coupled receptors. Can. J. PhysioL PharmacoL 80,375–382 (2002).
- Wong SK. G-protein selectivity is regulated by multiple intracellular regions of GPCRs. Neurosignals 12,1–12 (2003).
- Perez OD, Nolan GP. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nature BiotechnoL 20,155–162 (2002).
- Sills MA, Weiss D, Pham Q etal. Comparison of assay technologies for tyrosine kinase assay generates different results in high-throughput screening. BiomoL Screen. 7,191–214 (2002).
- Biotech 2003 Report. Burrill and Company. 66–115 (2003).
- Pelech S. Tracking cell signaling protein expression and phosphorylation by innovative proteomic solutions. CUIT: Pharma. BiotechnoL 5,69–77 (2004).
- Luker GD, Sharma V, Pica CM et al. Noninvasive imaging of protein—protein interactions in living animals. Proc. Natl Acad. Sci. USA 99,6961–6966 (2002)
- Murakoshi H, lino R, Kobayashi T et al. Single molecule imaging analysis of RAS activation in living cells. Proc. Natl Acad. Sci. USA 101,7317–7322 (2004).
Website
- PerkinElmer www.perkinelmer.com (Viewed September 2004)
- Molecular Probes www.probes.com (Viewed September 2004)
- Caliper Life Sciences www.caliper.com (Viewed September 2004)
- Luminex, Inc. www.luminex.com (Viewed September 2004)